Investigation of serum proteome alterations in human glioblastoma multiforme

Proteomics

Volumn 12, Issue 14, 2012, Pages 2378-2390

  Gollapalli, Kishore ^a   Ray, Sandipan ^a   Srivastava, Rajneesh ^a   Renu, Durairaj ^b   Singh, Prateek ^b   Dhali, Snigdha ^c   Bajpai Dikshit, Jyoti ^b   Srikanth, Rapole ^c   Moiyadi, Aliasgar ^d   Srivastava, Sanjeeva ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b Kirloskar Business Park ^*  (India)

^c NATIONAL CENTRE FOR CELL SCIENCE   (India)

^d TATA MEMORIAL HOSPITAL   (India)

Author keywords

2D DIGE; Biomedicine; Glioblastoma multiforme; Glioma; Serum biomarker

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMYLOID P COMPONENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN M; CERULOPLASMIN; CHOLESTEROL; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; INTER ALPHA TRYPSIN INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN; PREALBUMIN; PROTEOME; PROTHROMBIN; RETINOL BINDING PROTEIN; SERUM ALBUMIN; TRIACYLGLYCEROL; VITAMIN D BINDING PROTEIN;

ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; METASTASIS; MOLECULAR INTERACTION; PRECURSOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR GROWTH;

BAYES THEOREM; BLOOD PROTEINS; CASE-CONTROL STUDIES; DECISION TREES; DOWN-REGULATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GLIOBLASTOMA; HUMANS; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PROTEIN INTERACTION MAPS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84864564891     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200002     Document Type: Article

References (50)

1. Davis, F. G. R, Freels, S., Grutsch, J., Barlas, S. et al., Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J. Neurosurg. 1998, 88, 1-10.
2. Gurney, J. G., Kadan-Lottick, N., Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr. Opin. Oncol. 2001, 13, 160-166.
3. Kleihues, P., Louis, D. N., Scheithauer, B. W., Rorke, L. B. et al., The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 2002, 61, 215-225; discussion 226-229.
4. Ichimura, K., Ohgaki, H., Kleihues, P., Collins, V. P., Molecular pathogenesis of astrocytic tumours. J. Neurooncol. 2004, 70, 137-160.
5. Burden-Gulley, S. M., Gates, T. J., Burgoyne, A. M., Cutter, J. L. et al., A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. Neoplasia 2010, 12, 305-316.
6. Felsberg, J., Rapp, M., Loeser, S., Fimmers, R. et al., Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin. Cancer Res. 2009, 15, 6683-6693.
7. Cha, S., CNS tumors: monitoring therapeutic response and outcome prediction. Top. Magn. Reson. Imaging 2006, 17, 63-68.
8. Mischel, P. S., Nelson, S. F., Cloughesy, T. F., Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther. 2003, 2, 242-247.
9. Kumar, D. M., Thota, B., Shinde, S. V., Prasanna, K.V. et al., Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J. Proteome Res. 2010, 9, 5557-5567.
10. Schuhmann, M. U., Zucht, H. D., Nassimi, R., Heine, G. et al., Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur. J. Surg. Oncol. 2010, 36, 291-207.
11. Collet, B., Guitton, N., Saïkali, S., Avril, T. et al., Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci. 2011, 9, 16.
12. Ray, S., Reddy, P. J., Jain, R., Gollapalli, K. et al., Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11, 2139-2161.
13. Somasundaram, K., Nijaguna, M. B., Kumar, D. M., Serum proteomics of glioma: methods and applications. Expert Rev. Mol. Diagn. 2009, 9, 695-707.
14. Ray, S., Kamath, K. S., Srivastava, R., Raghu, D. et al., Serum proteome analysis of vivax malaria: an insight into the disease pathogenesis and host immune response. J. Proteomics 2012, 75, 3063-3080.
15. Shevchenko, A., Tomas, H., Havlis, J., Olsen, J. V. et al., In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat. Protoc. 2006, 1, 2856-2860.
16. Thomas, P. D., Kejariwal, A., Guo, N., Mi, H. et al., Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res. 2006, 34, W645-W650.
17. Huang da, W., Sherman, B. T., Lempicki, R. A., Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4, 44-57.
18. Niclou, S. P., Fack, F., Rajcevic, U., Glioma proteomics: status and perspectives. J. Proteomics 2010, 73, 1823-1838.
19. Hormigo, A., Gu, B., Karimi, S., Riedel, E. et al., YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res. 2006, 12, 5698-5704.
20. Jung, C. S., Foerch, C., Schänzer, A., Heck, A. et al., Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 2007, 130, 3336-3341.
21. Petrik, V., Saadoun, S., Loosemore, A., Hobbs, J. et al., Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin. Chem. 2008, 54, 713-722.
22. Sreekanthreddy, P., Srinivasan, H., Kumar, D. M., Nijaguna, M. B. et al., Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol. Biomarkers Prev. 2010, 19, 1409-1422.
23. Iwamoto, F. M., Hottinger, A. F., Karimi, S., Riedel, E. et al., Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J. Neurooncol. 2011, 105, 607-612.
24. Maragoudakis, M. E., Tsopanoglou, N. E., On the mechanism(s) of thrombin induced angiogenesis. Adv. Exp. Med. Biol. 2000, 476, 47-55.
25. O'Reilly, M. S., Pirie-Shepherd, S., Lane, W.S., Folkman, J., Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999, 285, 1926-1928.
26. Hua, Y., Tang, L., Keep, R. F., Schallert, T. et al., The role of thrombin in gliomas. J. Thromb. Haemost. 2005, 3, 1917-1923.
27. Harbeck, N., Schmitt, M., Kates, R. E., Kiechle, M. et al., Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin. Breast Cancer 2002, 3, 196-200.
28. Emonard, H., Grimaud, J. A., Matrix metalloproteinases. A review. Cell Mol. Biol. 1990, 36, 131-153.
29. Tsatas, D., Kaye, A. H., The role of the plasminogen activation cascade in glioma cell invasion: a review. J. Clin. Neurosci. 2003, 10, 139-145.
30. Mehrian-Shai, R., Chen, C. D., Shi, T., Horvath, S. et al., Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 5563-5568.
31. Shibuya, M., Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor. FEBS J. 2009, 276, 4636-4643.
32. Gousias, K., Markou, M., Arzoglou, V., Voulgaris, S. et al., Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J. Neuroimmunol. 2010, 226, 136-142.
33. Weiss, J. F., Morantz, R. A., Bradley, W. P., Chretien, P. B., Serum acute-phase proteins and immunoglobulins in patients with gliomas. Cancer Res. 1979, 39, 542-544.
34. Martínez-Hernández, R., Montes, S., Higuera-Calleja, J., Yescas, P. et al., Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study. Neurochem. Res. 2011, 36, 2111-2115.
35. Turecký, L., Kalina, P., Uhlíková, E., Námerová, S., Krizko, J., Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin. Wochenschr. 1984, 62, 187-189.
36. Patel, B. N., Dunn, R. J., Jeong, S. Y., Zhu, Q. et al., Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J. Neurosci. 2002, 22, 6578-6586.
37. Benedetti, E., Galzio, R., Laurenti, G., D'Angelo, B. et al., Lipid metabolism impairment in human gliomas: expression of peroxisomal proteins in human gliomas at different grades of malignancy. Int J Immunopathol. Pharmacol. 2010, 23, 235-246.
38. Hasan, H. R., Al-Samaraae, S. Sh., Study of lipoproteins in patients with brain tumors. Damascus Univ. J. Basic Sci. 2009, 25, 9-18.
39. Chao, F. C., Efron, B., Wolf, P., The possible prognostic usefulness of assessing serum proteins and cholesterol in malignancy. Cancer, 1975, 35, 1223-1229.
40. Srivastava, N. K., Pradhan, S., Gowda, G. A., Kumar, R., In vitro, high-resolution 1H and 31P NMR based analysis of the lipid components in the tissue, serum, and CSF of the patients with primary brain tumors: one possible diagnostic view. NMR Biomed. 2010, 23, 113-122.
41. Basdevant, A., Steroids and lipid metabolism: mechanism of action. Int. J. Fertil. 1992, 37(Suppl 2), 93-97.
42. Budd, D., Ginsberg, H., Hypocholesterolemia and acute myelogenous leukemia. Association between disease activity and plasma low-density lipoprotein cholesterol concentrations. Cancer 1986, 58, 1361-1365.
43. Alexopoulos, C. G., Blatsios, B., Averiginos, A., Serum lipid and lipoprotein disorders in cancer patients. Cancer 1987, 60, 3065-3070.
44. Chen, H. W., Kandutsch, A. A., Heiniger, H. J., The role of cholesterol in malignancy. Prog. Exp. Tumor Res. 1978, 22, 275-316.
45. Grieb, P., Ryba, M. S., Jagielski, J., Gackowski, W. et al., Serum cholesterol in cerebral malignancies. J. Neurooncol. 1999, 41, 175-180.
46. Diesel, B., Radermacher, J., Bureik, M., Bernhardt, R. et al., Vitamin D(3) metabolism in human glioblastoma multiforme: functionality of CYP27B1 splice variants, metabolism of calcidiol, and effect of calcitriol. Clin. Cancer Res. 2005, 11, 5370-5380.
47. Gomme, P. T., Bertolini, J., Therapeutic potential of vitamin D-binding protein. Trends Biotechnol. 2004, 22, 340-345.
48. Abbas, S., Linseisen, J., Slanger, T., Kropp, S. et al., The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol. Biomarkers Prev. 2008, 17, 1339-1343.
49. Magrassi, L., Adorni, L., Montorfano, G., Rapelli, S. et al., Vitamin D metabolites activate the sphingomyelin pathway and induce death of glioblastoma cells. Acta Neurochir. (Wien) 1998, 140, 707-713.
50. Rehder, D. S., Nelson, R. W., Borges, C. R., Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci. 2009, 18, 2036-2042.